Bolt Biotherapeutics, Inc. Common Stock
BOLT
BOLT: Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
moreShow BOLT Financials
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of BOLT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BOLT's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
-
Patent Title: Thienoazepine immunoconjugates, and uses thereof May. 23, 2023
-
Patent Title: Immunoconjugates targeting her2 Aug. 02, 2022
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on BOLT's company Twitter account
WallStreetBets
Number of mentions of BOLT in WallStreetBets Daily Discussion
BOLT News
Recent insights relating to BOLT
CNBC Recommendations
Recent picks made for BOLT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BOLT
Corporate Flights
Flights by private jets registered to BOLT